What Makes Bausch Health (BHC) Appear So Attractive

Group 1 - Bausch Health Companies Inc. (NYSE:BHC) is recognized as one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds [1] - Analyst Glen Santangelo from Barclays reduced the price target on Bausch Health from $8 to $7, maintaining an Equal Weight rating, indicating an adjusted upside potential of almost 37% despite the revision [1][2] - The company's fourth quarter report showed year-on-year growth in key financial metrics, attributed to its commercial and operational strength [3] Group 2 - CEO Thomas Appio highlighted the potential of the newly acquired full-service aesthetics distribution business in China, which enhances the company's geographical reach and customer access [3] - Bausch Health operates in various segments including hepatology, neurology, dermatology, gastroenterology, generic pharmaceuticals, over-the-counter items, aesthetic medical devices, and eye health [3] - The company is committed to commercial and operational excellence and aims to expand its portfolio and enhance its long-term outlook as it moves into 2026 [3]